First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as
Monotherapy and in Combination With Other Antineoplastic Agents in
Participants With Advanced Solid Tumors
Monotherapy and in Combination With Other Antineoplastic Agents in
Participants With Advanced Solid Tumors
Phase: Phase I-II clinical trials
Principal Investigator: Dott.ssa Bianchi Giulia Valeria
Main Facility: Oncologia Medica 1
Drug: Cohort A: STX-478
Cohort B: STX-478 + fulvestrant or STX-478 +
letrozole/anastrozole/exemestane
Cohort C/D/E: STX-478 + endocrine therapy + CDK4/6 inhibitor
Pathologies: Breast cancer
ClinicalTrials.gov: Read more about clinical trials
A Phase 1/2, multicenter, interventional, non-randomized, open-label clinical study conducted in patients with HR+/HER2- advanced or metastatic breast cancer with an active PI3Kα mutation, confirmed by central histology review and molecular testing. The primary purpose is to characterize the safety, tolerability, pharmacokinetic profile, and preliminary antitumor activity of STX-478, both alone and in combination with other standard treatments.
Patients are enrolled in sequential cohorts: in the dose-escalation phase, they receive STX-478 monotherapy at increasing doses to determine the maximum tolerated dose and the recommended dose for Phase 2, while in the dose-expansion phase, HR+/HER2- breast cancer-specific cohorts receive STX-478 alone or in combination with standard endocrine therapies and/or CDK4/6 inhibitors
Last update: 12/05/2026